Every connective tissue in the body contains some form of extracellular matrix, which acts as scaffolding, provides a surface for cell attachment, and gives the tissue its shape and mechanical properties. This is foundational cell biology, described in tissue types across the body, not a feature specific to any one commercial source.
Commercial Wharton's jelly product studies, including a 2026 analysis of six products, have reported low total cell counts and low cell viability, with only rare viable mesenchymal stromal cells identified. Request a lot-specific composition and viability breakdown from the supplier rather than assuming those findings describe a different product or lot.
When evaluating documentation, ask the supplier to clarify whether a given specification describes matrix composition or donor cell content, since these are different measurements that may appear in different sections of a certificate of analysis or product insert. Treating one as a stand-in for the other can lead to a misreading of what the product actually contains.
Understanding ECM helps a buyer see why a cord-tissue product is often described in terms of matrix content rather than as a source of living cells.